We are live on
!
Find out more
Dianthus Therapeutics
DNTH
DNTH
54 hedge funds and large institutions have $125M invested in Dianthus Therapeutics in 2018 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 15 increasing their positions, 16 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
40% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 10
6% more funds holding
Funds holding: 51 → 54 (+3)
1.58% more ownership
Funds ownership: 2.57% → 4.15% (+1.6%)
6% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 16
23% less capital invested
Capital invested by funds: $162M → $125M (-$37M)
Holders
54
Holders Change
+3
Holders Change %
+5.88%
% of All Funds
1.2%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
14
Increased
15
Reduced
16
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$3.52M |
| 2 |
CC
Casdin Capital
New York
|
+$3.34M |
| 3 |
BlackRock
New York
|
+$3.28M |
| 4 |
Bessemer Group
Woodbridge,
New Jersey
|
+$2.02M |
| 5 |
ACA
Anchor Capital Advisors
Boston,
Massachusetts
|
+$1.55M |
Top Sellers
| 1 |
VOYA Investment Management
Atlanta,
Georgia
|
-$2.99M |
| 2 |
Fidelity International
Hamilton,
Bermuda
|
-$2.79M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$2.04M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.87M |
| 5 |
NC
Nexthera Capital
New York
|
-$1.8M |
